Table 2: Ongoing trials of vitamin D supplementation.

NameLocationStudy population, DoseOutcomesCurrent statusYear results expected

VITALUS20,000 
Men, age 50+ 
Women, age 55+
2000 IU/dCancer, cardiovascular diseaseRecruiting until 20122017
ViDANew Zealand5100 
Age 50+
100,000 IU/mo
(3300 IU/d)
Cardiovascular disease, respiratory disease, fractureRecruiting until 20122017
DOHealthEurope2150 
Age 70+
2000 IU/dBlood pressure, fracture, infectious disease, cognition, physical functionRecruitment ongoing2017
FINDFinland18,000 
Men, age 60+ 
Women, age 65+
1600 IU/d
3200 IU/d
Cancer, cardiovascular disease, diabetesStarting recruitment in 20132020
VIDALUK20,000 
Age 65–84
60,000 IU/mo
(2000 IU/d)
Longevity and other outcomesOngoing recruitment of 1600 for feasibility2020